Bristol Myers Squibb announced plans to acquire RayzeBio for USD 4.1 billion. This move aligns with Bristol Myers Squibb’s strategy to expand its oncology pipeline. RayzeBio’s expertise in targeted radiopharmaceuticals for cancer treatment will complement Bristol Myers Squibb’s existing portfolio. The acquisition is expected to enhance the company’s ability to develop innovative therapies for patients with cancer. This aligns with Bristol Myers Squibb’s commitment to advancing cancer research and improving patient outcomes. The deal reflects the company’s investment in cutting-edge technologies and novel treatment approaches in the fight against cancer.
Source link
Bristol Myers Squibb to acquire RayzeBio for USD 4.1 billion
